Amneal Pharmaceuticals' Shares Rise After JPMorgan Upgrade

MT Newswires Live

02-25

Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.

The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.

Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.

Price: 8.60, Change: +0.77, Percent Change: +9.77

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514563776"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514563776\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514563776?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514563776","market":"sg","top_or_hot":-1,"title":"Amneal Pharmaceuticals' Shares Rise After JPMorgan Upgrade","media":"MT Newswires Live","content":"<html><body><p> Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.</p><p>The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.</p><p>Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.</p><p>Price: 8.60, Change: +0.77, Percent Change: +9.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals' Shares Rise After JPMorgan Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals' Shares Rise After JPMorgan Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-25 00:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.</p><p>The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.</p><p>Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.</p><p>Price: 8.60, Change: +0.77, Percent Change: +9.77</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514563776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514563776","pubTimestamp":1740415058,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amneal Pharmaceuticals'  shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.Price: 8.60, Change: +0.77, Percent Change: +9.77","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc."},"translate_title":"摩根大通升级后Amneal Pharmaceuticals股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":0.9},"content_text":"Amneal Pharmaceuticals' (AMRX) shares rose nearly 10% in recent Monday trading after JPMorgan upgraded the stock to overweight from neutral and adjusted its price target to $12 from $9.The drugmaker said last week that it is set to launch mesalamine 800-milligram delayed-release tablets to treat moderately active ulcerative colitis in adults. The company added it had received approval from the US Food and Drug Administration for an abbreviated new drug application for lenalidomide capsules, which are used to treat blood cancers.Trading volume stood at about 2.4 million shares against a daily average of more than 1.1 million shares.Price: 8.60, Change: +0.77, Percent Change: +9.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}